InvestorsHub Logo
Followers 833
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

Re: BlackDoggie post# 2533

Friday, 02/24/2017 1:56:38 PM

Friday, February 24, 2017 1:56:38 PM

Post# of 4867
HIV patients are suited for a CCR5 agent only if they test positive on a CCR5 assay. The need to obtain such an assay reduces the commercial prospects.

From the FDA label for Selzentry (http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208984_022128s017lbl.pdf )

INDICATIONS AND USAGE

SELZENTRY is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in patients 2 years of age and older weighing at least 10 kg.

Limitations of Use:
Not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

DOSAGE AND ADMINISTRATION

Prior to initiation of SELZENTRY, test all patients for CCR5 tropism using a highly sensitive tropism assay.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GILD News